TABLE 2.

Associations of ctDNA Mutational Status and PSMA PET Parameters with Outcome Measures

		Outcome variable
		PSA50-RR		PSA PFS		OS
Parameter	Prevalence (n)	Rate (%)	P	Hazard ratio	P	Hazard ratio	P
ctDNA analysis
HRR	14/39 (36%)	43 vs. 52	0.42	1.24 (0.61–2.55)	0.55	1.38 (0.58–3.32)	0.47
PI3K	15/39 (39%)	62 vs. 42	0.31	0.82 (0.39–1.70)	0.59	1.29 (0.53–1.15)	0.57
AVPC	9/39 (23%)	38 vs. 52	0.69	2.33 (1.01–5.39)	0.04	1.89 (0.72–4.96)	0.19
TMPRSS2-ERG	10/39 (26%)	67 vs. 43	0.27	1.03 (0.47–2.22)	0.95	0.92 (0.36–2.39)	0.87
AR	16/39 (41%)	47 vs. 50	1.00	1.13 (0.56–2.27)	0.74	2.10 (0.89–5.02)	0.09
PSMA PET analysis
SUV_mean < 10	45/71 (63%)	30 vs. 56	0.04	1.75 (1.02–3.03)	0.04	0.87 (0.43–1.72)	0.68
Unfavorable outcome	15/71 (21%)^*	19 vs. 46	0.04	2.00 (1.19–3.40)	0.01	4.00 (1.95–8.20)	<0.001
	32/71 (45%)^†
	27/71 (38%)^‡
PSMA-NR	18/71 (25%)	6 vs. 51	0.007	4.56 (2.42–8.57)	<0.001	2.13 (1.01–4.55)	0.04

↵* Prevalence of unfavorable outcome by LuPSMA nomogram for PSA50-RR.
↵† Prevalence of unfavorable outcome by LuPSMA nomogram for PSA PFS.
↵‡ Prevalence of unfavorable outcome by LuPSMA nomogram for OS.
Rates are calculated for presence vs. absence of outcome predictor. Hazard ratios are calculated for presence vs. absence of outcome predictor; parenthetic data following hazard ratios are 95% CIs.